Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers

The antithrombotic activity and pharmacokinetics of Clivarin®, a low molecular weight heparin was randomly studied in 10 healthy male volunteers. Doses of 20, 40, 60 and 80 anti F Xa U/kg BW were injected intravenously and subcutaneously in crossover fashion. The heparin concentrations were measured...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrassy, Konrad (Author) , Eschenfelder, Volker (Author) , Koderisch, Janti (Author) , Weber, E. (Author)
Format: Article (Journal)
Language:English
Published: 1994
In: Thrombosis research
Year: 1994, Volume: 73, Issue: 2, Pages: 95-108
ISSN:1879-2472
DOI:10.1016/0049-3848(94)90084-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/0049-3848(94)90084-1
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/0049384894900841
Get full text
Author Notes:K. Andrassy, V. Eschenfelder, J. Koderisch, E. Weber
Description
Summary:The antithrombotic activity and pharmacokinetics of Clivarin®, a low molecular weight heparin was randomly studied in 10 healthy male volunteers. Doses of 20, 40, 60 and 80 anti F Xa U/kg BW were injected intravenously and subcutaneously in crossover fashion. The heparin concentrations were measured by inhibition of clotting assays (anti Ila and anti Xa activities using amidolytic assays and (dilute) thrombin time. The pharmacokinetic profile of Clivarin® is characterized by a linear relationship between dose and absorption, relatively low clearance and a long elimination half-life, and a high anti Xa/anti Ila ratio of 5.3.
Item Description:Elektronische Reproduktion der Druck-Ausgabe 9. April 2004
Gesehen am 27.09.2023
Physical Description:Online Resource
ISSN:1879-2472
DOI:10.1016/0049-3848(94)90084-1